Progress Software (NASDAQ:PRGS) is scheduled to announce Q2 earnings results on Thursday, June 27th, after market close. PRGS looks very appealing pre earnings as it has quite a good record of earnings beats and given the fact that the stock is now about to fill post earnings gaps on the chart, we think a notable bounce could be on the way very soon if not...
BLOCKCHAIN DEAL WITH RIPPLE The Dallas, Texas.-based money transfer company is entering the blockchain industry by agreeing to a deal with Ripple, which is behind the cryptocurrency XRP. The agreement involves an investment of up to $50 million at prices that are roughly three times the closing price of MGI stock. MoneyGram will use Ripple’s XRP technology for...
KEEP ALERTS SET FOR A BREAK OF $105, WHICH COULD RESULT IN A VERY NASTY FALL BACK DOWN TO THE GAP UP LEVEL $75, AVERAGE ANALYSTS ESTIMATE $162.20 AVERAGE ANALYSTS RECOMMENDATION BUY COMPANY PROFILE Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of...
KEEP ON STRONG WATCH FOR A BREAKOUT ON CONTINUATION AFTER A SEVERAL STRONG TRADING SESSIONS. ALERT SET FOR BREAK OF $.91 FOR PROJECTED TARGET OF $1.30. SPECULATIVE AND RISKY. AVERAGE ANALYSTS PRICE TARGET $1.50 AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT COMPANY PROFILE TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted...
===================== CMPY (Comepay Inc.) Alert Price: $1.34 Float: 4.947M Website | Recent News ======================== Members, Earlier today we promised to deliver you a bottom'd out alert with tons of upside potential. Please turn your immediate attention to CMPY (Comepay Inc.). An Epic Bounce Could be in the Making for this Low-Float Company...
The recent reverse split has not helped the stock, it just makes the stock even worse from a technical perspective. There is really nothing to cling your hopes to on the chart, the only positive is that it is so bad that any earnings surprise could produce a great bounce, but just because the stock price is low does not mean it is cheap. AVERAGE ANALYSTS PRICE...
NG has had a 55% move in a matter of one month, by any standards that is parabolic and such moves often end in disaster for those late to the party. AS GOLD had broken out so has the many ETF,s that follow the commodity which explains why even the lesser companies are moving at such a pace. Given the paper profits within the sector any sell off could be very...
After a initial drop on the news of the $175million offering the stock did drop but has since rebounded and extended the gains and the momentum looks to continues with $25 as a reasonable short term target. Proceeds of the offering will go toward expanding development of ZW25 (as a single agent and in combination), expanding developing of ZW49 through an ongoing...
Zynex operates through the Electrotherapy and Pain Management Products segment. The company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. - ZMI. Its other subsidiaries include Zynex Monitoring Solutions, Inc. - ZMS and Zynex Europe, ApS - ZEU. ZMI designs, manufactures and markets medical devices that treat...
RA PHARMACEUTICALS HAS BEEN BUILDING A BASE FOR 2 YEARS AND IS NOW ON THE VERGE OF BREAKING OUT FROM A CUP AND HANDLE FORMATION. VOLUME HAS INCREASED CONSIDERABLY WHICH IS VERY POSITIVE AS IS ALL THEY INDICATORS. $28 IS THE LEVEL TO WATCH FOR WHAT COULD BE A EPIC BREAKOUT. AVERAGE ANALYSTS PRICE TARGET $40.33 AVERAGE ANALYSTS RECOMMENDATION BUY COMPANY...
Investors eagerly await the FDA verdict on its NDA for Edviso, which is being evaluated for the treatment of vascular Ehlers -Danlos syndrome in patients with a confirmed type 111 collagen mutation. This for sure will be a market moving event. AVERAGE ANALYSTS PRICE TARGET $51.40 AVERAGE RECOMMENDATION BUY COMPANY PROFILE Acer Therapeutics, Inc. is a...
===================== PRED (Predictive Technology Group Inc.) Alert Price: $4.60 Zack's Price Target: $8.00 Zack's Small Cap Research Report Investor Presentation Chart Analysis Website | Recent News ======================== Members, The biotech industry has kept its promise for solid returns so far. The rally in some major biotechnology indexes...
Tilray leads the pack for another day on the heels off a major reversal from the open as it sold off in sympathy with Canopy, but the buyers appeared quickly and is now approaching resistance. Having such a short interest, could add fuel to the fire in the coming days, as the options activity also indicates a significant bullish move. Will consider adding to...
The company has a recent failed trial but has many more in the pipeline, this may be the catalysts for the increase in option trades in the past month. There has also been notable insider buying in May and the company has a strong balance sheet. We will be keeping a very close eye on the newsflow regarding trial updates. AVERAGE ANALYSTS PRICE TARGET ...
It has come to light that several suitors are now in play to take over the retail division, thus the rally in the stock today, which was at EXTREMELY Beaten down level. THE STOCK ALSO CARRIES A INCREDIBLE 65% SHORT INTEREST, and is just about the most expensive stock to borrow. "Two very attractive acquirers that I would have put high up on my list have shown...
Possible trading opportunity in the beaten down media stock tomorrow after getting a outperform rating from Oppenheimer and a 100% upside price target of $7. AVERAGE ANALYSTS PRICE TARGET $7.31 AVERAGE ANALYSTS RECOMMENDATION BUY COMPANY PROFILE The Meet Group, Inc. engages in the provision of mobile social entertainment apps designed for human...
Mustang Bio (NASDAQ:MBIO) is up 8.6% after hours following an bullish initiation at Overweight by Cantor, setting a $7s price target, implying 108% upside from today's close. This price target is actually considerable lower that the previous average of $19.50. COMPANY PROFILE Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the...
The company really is in considerable trouble given the latest sales figures and the increased competition entering the sector. Just like TSLA sentiment has turned very sour in the markets and the have both become whipping boys and a target for mockery. Although the stock is very cheap it can easily drop further so we think a rise above the Middle BB on continued...